Suven Life Sciences Limited
Bombay Stock ExchangeTotal Valuation
Suven Life Sciences Limited carries a market capitalization of 70.51B, placing it among publicly traded companies globally. Its enterprise value stands at 24.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 70.51B |
| Enterprise Value | 24.51B |
Share Statistics
Suven Life Sciences Limited currently has 263.72M shares outstanding.
| Shares Outstanding | 263.72M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 415.55, and the price-to-book ratio stands at 112.11.
| PE Ratio | N/A |
| PS Ratio | 415.55 |
| PB Ratio | 112.11 |
| P/TBV Ratio | 5.00 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 344.55 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 15,534.63 |
Financial Position
Suven Life Sciences Limited maintains a current ratio of 17.69, meaning it holds 17.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.82, indicating elevated leverage, while an interest coverage ratio of -1,838.51 demonstrates limited ability to service its debt obligations.
| Current Ratio | 17.69 |
| Quick Ratio | 16.89 |
| Debt / Equity | 2.82 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | -1,838.51 |
Financial Efficiency
| Return on Equity (ROE) | -951.14 |
| Return on Assets (ROA) | -72.78 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Suven Life Sciences Limited's stock has gained approximately 17.74163% over the past 52 weeks. The 50-day moving average sits at 160.30, while the 200-day moving average is 203.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | 17.74163% |
| 50-Day Moving Average | 160.30 |
| 200-Day Moving Average | 203.05 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Suven Life Sciences Limited generated 71.15M in revenue and converted that into -2.76B in net income, yielding earnings per share of -12.42. EBITDA reached -2.90B, while operating income came in at -2.90B.
| Revenue | 71.15M |
| Gross Profit | 71.15M |
| Operating Income | -2.90B |
| Pretax Income | -2.76B |
| Net Income | -2.76B |
| EBITDA | -2.90B |
| EBIT | -2.90B |
| Earnings Per Share (EPS) | -12.42 |
Balance Sheet
Suven Life Sciences Limited holds 5.22B in cash and equivalents against 166.94M in total debt, resulting in a net debt position of -82.79M. Total book value stands at 263.72M, with working capital of 5.16B providing operational flexibility.
| Cash & Cash Equivalents | 5.22B |
| Total Debt | 166.94M |
| Net Debt | -82.79M |
| Equity (Book Value) | 263.72M |
| Book Value Per Share | 1.19 |
| Working Capital | 5.16B |
Margins
Suven Life Sciences Limited operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -4,077.70 and net profit margin of -3,884.13 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -4,077.70 |
| Pretax Margin | -3,884.13 |
| Profit Margin | -3,884.13 |
| EBITDA Margin | -4,077.70 |
Stock Splits
Suven Life Sciences Limited's most recent stock split took place on October 17, 2022 with a 200:217 split ratio.
| Last Split Date | 10/17/2022 |
| Split Ratio | 200:217 |
Scores
Suven Life Sciences Limited posts an Altman Z-Score of 53.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 53.53 |